美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Kyverna Therapeutics

5.77

-0.4400-7.09%

盘后：5.820.0500+0.87%19:30 EDT

成交量：124.15万

成交额：730.18万

市值：3.57亿

市盈率：-2.00

高：6.17

开：6.17

低：5.76

收：6.21

52周最高：13.67

52周最低：5.76

股本：6,184.34万

流通股本：3,971.50万

量比：1.55

换手率：3.13%

股息：- -

股息率：- -

每股收益(TTM):-2.8809

每股收益(LYR):-3.6445

净资产收益率：-87.24%

总资产收益率：-44.51%

市净率：2.16

市盈率(LYR):-1.58

数据加载中...

总览公司新闻资讯公告

健康快讯：研究显示，阑尾切除与结直肠癌风险降低有关

Kyverna股价上涨，因细胞疗法在罕见神经疾病中显现持久疗效

Kyverna Therapeutics公布Miv-Cel治疗僵人综合征与全身性重症肌无力一年期积极数据：持久临床缓解与良好安全性获验证

Kyverna Therapeutics 与 Elevatebio 达成 Miv-Cel 商业生产与供应协议

生物技术专家希望美国食品药品监督管理局（FDA）的药物评审基于科学，而非政治

纳斯达克生物科技指数一度跌超3%，成分股Kyverna Therapeutics目前跌12.45%，Prime Medi

Kyverna Therapeutics任命Ritesh Srivastava为首席法律与合规官，强化领导团队以支持商业化阶段转型

《健康巡诊》：CAR-T疗法为移植选择有限的肾病患者带来希望

《健康巡诊》：CAR-T疗法为移植选择有限的肾病患者带来希望

Kyverna Therapeutics在欧洲风湿病学年会上公布Miv-Cel最新数据，显示其对ACPA阳性、难治性类风湿关节炎疾病活动度有显著降低作用

Kyverna Therapeutics任命神经学与罕见疾病领域资深商业领袖Nadia Dac为首席商务官

Kyverna Therapeutics股价大涨7.3% 罕见肌肉疾病细胞疗法中期数据表现强劲

BUZZ--美国股票走势-Adobe、GE Vernova、Calix

BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升

Kyverna Therapeutics股价盘前飙升21% 中期试验显示其疗法改善僵人综合征患者活动能力

Kyverna Therapeutics公布KYSA-8试验主要分析结果：Miv-Cel治疗SPS取得积极成效

Kyverna Therapeutics公布Miv-Cel治疗全身型重症肌无力二期长期积极数据

Kyverna Therapeutics：24周时100%患者实现MG-ADL与QMG快速持续改善

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/KYTX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KYTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","market":"US","secType":"STK","nameCN":"Kyverna Therapeutics","latestPrice":5.77,"timestamp":1791921600000,"preClose":6.21,"halted":0,"volume":1241476,"hourTrading":{"tag":"盘后","latestPrice":5.82,"preClose":5.77,"latestTime":"19:30 EDT","volume":241795,"amount":1396982.3644,"timestamp":1791934204112,"change":0.05,"changeRate":0.008666,"amplitude":0.031196},"delay":0,"changeRate":-0.07085346215781005,"floatShares":39715000,"shares":61843444,"eps":-2.880877,"marketStatus":"已收盘","change":-0.44,"latestTime":"10-13 16:00:00 EDT","open":6.17,"high":6.17,"low":5.755,"amount":7301800.06411,"amplitude":0.066828,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.880877,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791964800000},"marketStatusCode":5,"adr":0,"listingDate":1707368400000,"exchange":"NASDAQ","adjPreClose":6.21,"preHourTrading":{"tag":"盘前","latestPrice":6.16,"preClose":6.21,"latestTime":"09:29 EDT","volume":232,"amount":1436.9099336000002,"timestamp":1791898199999,"change":-0.05,"changeRate":-0.008052,"amplitude":0.056361},"postHourTrading":{"tag":"盘后","latestPrice":5.82,"preClose":5.77,"latestTime":"19:30 EDT","volume":241795,"amount":1396982.3644,"timestamp":1791934204112,"change":0.05,"changeRate":0.008666,"amplitude":0.031196},"volumeRatio":1.5516,"impliedVol":1.3077,"impliedVolPercentile":0.5618},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KYTX\",,,,,undefined,":{"symbol":"KYTX","floatShares":39715000,"roa":"-44.51%","roe":"-87.24%","lyrEps":-3.644532,"volumeRatio":1.5516,"shares":61843444,"dividePrice":0,"high":6.17,"amplitude":0.066828,"preClose":6.21,"low":5.755,"week52Low":5.755,"pbRate":"2.16","psRate":"1265.38","week52High":13.67,"institutionHeld":0,"latestPrice":5.77,"eps":-2.880877,"divideRate":0,"volume":1241476,"delay":0,"ttmEps":-2.880877,"open":6.17,"prevYearClose":9.4,"prevWeekClose":6.39,"prevMonthClose":6.8,"prevQuarterClose":6.8,"fiveDayClose":6.16,"twentyDayClose":6.96,"sixtyDayClose":7.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KYTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"KYTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.67,"name":null,"time":"盘后","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"post","actualEps":-0.63},{"market":"US","date":"2026-05-12","symbol":"KYTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"盘后","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.66},{"market":"US","date":"2026-03-26","symbol":"KYTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.8,"name":null,"time":"盘后","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.8},{"market":"US","date":"2025-11-12","symbol":"KYTX","fiscalQuarterEnding":"2025/09","expectedEps":-0.97,"name":null,"time":"盘后","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"post","actualEps":-0.85},{"market":"US","date":"2025-08-12","symbol":"KYTX","fiscalQuarterEnding":"2025/06","expectedEps":1,"name":null,"time":"盘后","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-0.97}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KYTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KYTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1755748800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KYTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KYTX","date":"2026-10-12","current":-2.002862,"percent":0.565022,"low":-26.836094,"twenty":-4.171771,"median":-2.865887,"eighty":-1.134535,"high":-0.615209,"avg":-4.258583,"sd":5.550824,"marketCap":395179607},"quantilePoints":[{"date":"2024-02-09","current":-25.410847,"twenty":-24.055602,"median":-22.022734,"eighty":-19.989866,"marketCap":1224675750},{"date":"2024-02-16","current":-26.541682,"twenty":-26.641604,"median":-26.505996,"eighty":-25.427787,"marketCap":1279176368},{"date":"2024-02-23","current":-24.230994,"twenty":-26.541682,"median":-25.495549,"eighty":-24.578936,"marketCap":1167812779},{"date":"2024-03-01","current":-24.239916,"twenty":-26.505996,"median":-25.105309,"eighty":-24.54325,"marketCap":1168242754},{"date":"2024-03-08","current":-25.676289,"twenty":-26.318643,"median":-25.069622,"eighty":-24.578936,"marketCap":1237468769},{"date":"2024-03-15","current":-26.354329,"twenty":-26.354329,"median":-25.311608,"eighty":-24.712759,"marketCap":1270146888},{"date":"2024-03-22","current":-23.999034,"twenty":-26.354329,"median":-25.16776,"eighty":-24.239916,"marketCap":1156633422},{"date":"2024-03-28","current":-17.2201,"twenty":-26.32578,"median":-25.042858,"eighty":-23.820602,"marketCap":1039508532},{"date":"2024-04-05","current":-15.927342,"twenty":-26.311505,"median":-24.815357,"eighty":-20.313915,"marketCap":961469941},{"date":"2024-04-12","current":-17.062969,"twenty":-25.959995,"median":-24.578936,"eighty":-17.608641,"marketCap":1030023179},{"date":"2024-04-19","current":-13.577524,"twenty":-25.715544,"median":-24.235455,"eighty":-16.573007,"marketCap":819620788},{"date":"2024-04-26","current":-11.384836,"twenty":-25.597779,"median":-23.86521,"eighty":-16.071617,"marketCap":687256989},{"date":"2024-05-03","current":-10.734886,"twenty":-25.51207,"median":-23.093494,"eighty":-15.443094,"marketCap":648022117},{"date":"2024-05-10","current":-10.427767,"twenty":-25.427787,"median":-18.634621,"eighty":-13.461819,"marketCap":629482562},{"date":"2024-05-17","current":-8.660987,"twenty":-25.252064,"median":-17.663681,"eighty":-11.317698,"marketCap":657507471},{"date":"2024-05-24","current":-7.059414,"twenty":-25.176682,"median":-17.2201,"eighty":-10.732029,"marketCap":535922482},{"date":"2024-05-31","current":-7.116207,"twenty":-25.108877,"median":-16.627288,"eighty":-10.256351,"marketCap":540234007},{"date":"2024-06-07","current":-7.456968,"twenty":-25.053564,"median":-16.309455,"eighty":-9.030538,"marketCap":566103153},{"date":"2024-06-14","current":-5.412407,"twenty":-25.026799,"median":-16.020192,"eighty":-8.479248,"marketCap":410888275},{"date":"2024-06-21","current":-4.390126,"twenty":-24.958995,"median":-15.870204,"eighty":-7.953341,"marketCap":333280836},{"date":"2024-06-28","current":-4.259502,"twenty":-24.826956,"median":-14.259614,"eighty":-7.613717,"marketCap":323364330},{"date":"2024-07-05","current":-3.978375,"twenty":-24.748445,"median":-13.641804,"eighty":-7.429707,"marketCap":302022284},{"date":"2024-07-12","current":-5.56007,"twenty":-24.685994,"median":-12.649024,"eighty":-7.150283,"marketCap":422098238},{"date":"2024-07-19","current":-5.685015,"twenty":-24.571799,"median":-11.216991,"eighty":-6.028046,"marketCap":431583592},{"date":"2024-07-26","current":-5.588466,"twenty":-24.482583,"median":-10.813451,"eighty":-5.596417,"marketCap":424254000},{"date":"2024-08-02","current":-4.117518,"twenty":-24.238132,"median":-10.584898,"eighty":-5.421494,"marketCap":312585519},{"date":"2024-08-09","current":-3.725644,"twenty":-24.184602,"median":-9.999228,"eighty":-5.056881,"marketCap":282836000},{"date":"2024-08-16","current":-3.830678,"twenty":-23.972269,"median":-9.395703,"eighty":-4.700218,"marketCap":290809782},{"date":"2024-08-23","current":-4.597951,"twenty":-23.820602,"median":-8.80297,"eighty":-4.562778,"marketCap":349058032},{"date":"2024-08-30","current":-4.56385,"twenty":-23.561877,"median":-8.433813,"eighty":-4.558634,"marketCap":346469221},{"date":"2024-09-06","current":-4.171688,"twenty":-23.2407,"median":-8.189602,"eighty":-4.480996,"marketCap":316697893},{"date":"2024-09-13","current":-4.092119,"twenty":-22.946288,"median":-7.78069,"eighty":-4.395806,"marketCap":310657334},{"date":"2024-09-20","current":-3.631756,"twenty":-20.733738,"median":-7.624508,"eighty":-4.308092,"marketCap":275708384},{"date":"2024-09-27","current":-2.97247,"twenty":-18.634621,"median":-7.456968,"eighty":-4.211473,"marketCap":225658035},{"date":"2024-10-04","current":-2.63146,"twenty":-17.741488,"median":-7.394495,"eighty":-4.171688,"marketCap":199769924},{"date":"2024-10-11","current":-2.983837,"twenty":-17.707293,"median":-7.116207,"eighty":-4.052335,"marketCap":226520973},{"date":"2024-10-18","current":-3.205494,"twenty":-17.620069,"median":-6.641982,"eighty":-3.978375,"marketCap":243348245},{"date":"2024-10-25","current":-2.909952,"twenty":-17.56293,"median":-5.951944,"eighty":-3.964176,"marketCap":220911882},{"date":"2024-11-01","current":-2.779231,"twenty":-17.2201,"median":-5.608344,"eighty":-3.873307,"marketCap":210988106},{"date":"2024-11-08","current":-3.006571,"twenty":-17.062969,"median":-5.514635,"eighty":-3.751109,"marketCap":228246847},{"date":"2024-11-15","current":-1.697135,"twenty":-16.627288,"median":-5.392529,"eighty":-3.322005,"marketCap":187796512},{"date":"2024-11-22","current":-1.712741,"twenty":-16.355881,"median":-5.065967,"eighty":-3.177076,"marketCap":189523376},{"date":"2024-11-29","current":-2.251143,"twenty":-16.350167,"median":-4.969419,"eighty":-3.054313,"marketCap":249100201},{"date":"2024-12-06","current":-1.775165,"twenty":-16.285886,"median":-4.789428,"eighty":-3.003161,"marketCap":196430834},{"date":"2024-12-13","current":-1.724446,"twenty":-16.121613,"median":-4.674093,"eighty":-2.977017,"marketCap":190818525},{"date":"2024-12-20","current":-1.560584,"twenty":-16.033048,"median":-4.573541,"eighty":-2.950873,"marketCap":172686448},{"date":"2024-12-27","current":-1.556683,"twenty":-15.964482,"median":-4.562178,"eighty":-2.903132,"marketCap":172254731},{"date":"2025-01-03","current":-1.599599,"twenty":-15.904487,"median":-4.538274,"eighty":-2.797418,"marketCap":177003609},{"date":"2025-01-10","current":-1.346004,"twenty":-15.82735,"median":-4.480996,"eighty":-2.693979,"marketCap":148942061},{"date":"2025-01-17","current":-1.299186,"twenty":-15.443094,"median":-4.435561,"eighty":-2.615547,"marketCap":143761467},{"date":"2025-01-24","current":-1.404526,"twenty":-14.591731,"median":-4.395806,"eighty":-2.532048,"marketCap":155417803},{"date":"2025-01-31","current":-1.264073,"twenty":-13.927497,"median":-4.353211,"eighty":-2.095084,"marketCap":139876022},{"date":"2025-02-07","current":-1.170438,"twenty":-13.706085,"median":-4.259502,"eighty":-1.931223,"marketCap":129514836},{"date":"2025-02-14","current":-1.182143,"twenty":-13.577524,"median":-4.21845,"eighty":-1.814179,"marketCap":130809984},{"date":"2025-02-21","current":-1.084606,"twenty":-13.114702,"median":-4.187318,"eighty":-1.73693,"marketCap":120017081},{"date":"2025-02-28","current":-1.108015,"twenty":-12.719019,"median":-4.171688,"eighty":-1.688552,"marketCap":122607378},{"date":"2025-03-07","current":-1.01438,"twenty":-12.020501,"median":-4.104819,"eighty":-1.598038,"marketCap":112246191},{"date":"2025-03-14","current":-0.975365,"twenty":-11.480543,"median":-3.998252,"eighty":-1.555903,"marketCap":107929030},{"date":"2025-03-21","current":-0.928548,"twenty":-11.116285,"median":-3.978412,"eighty":-1.525471,"marketCap":102748436},{"date":"2025-03-28","current":-0.678003,"twenty":-10.923443,"median":-3.972766,"eighty":-1.481775,"marketCap":86429836},{"date":"2025-04-04","current":-0.671223,"twenty":-10.829164,"median":-3.959945,"eighty":-1.403746,"marketCap":85565537},{"date":"2025-04-11","current":-0.698343,"twenty":-10.750599,"median":-3.915931,"eighty":-1.33508,"marketCap":89022731},{"date":"2025-04-17","current":-0.630601,"twenty":-10.726315,"median":-3.836362,"eighty":-1.299186,"marketCap":80387103},{"date":"2025-04-25","current":-0.711969,"twenty":-10.557757,"median":-3.76816,"eighty":-1.283581,"marketCap":90759633},{"date":"2025-05-02","current":-0.772995,"twenty":-10.436338,"median":-3.711325,"eighty":-1.243785,"marketCap":98539030},{"date":"2025-05-09","current":-0.715359,"twenty":-10.170644,"median":-3.266591,"eighty":-1.184484,"marketCap":91191822},{"date":"2025-05-16","current":-0.68951,"twenty":-9.982087,"median":-3.188443,"eighty":-1.152492,"marketCap":100267785},{"date":"2025-05-23","current":-0.73409,"twenty":-9.837812,"median":-3.142975,"eighty":-1.119719,"marketCap":106750616},{"date":"2025-05-30","current":-0.781642,"twenty":-9.466412,"median":-3.049198,"eighty":-1.09553,"marketCap":113665635},{"date":"2025-06-06","current":-0.873775,"twenty":-9.030538,"median":-3.023622,"eighty":-1.030766,"marketCap":127063486},{"date":"2025-06-13","current":-1.02832,"twenty":-8.929052,"median":-2.986679,"eighty":-1.018767,"marketCap":149537300},{"date":"2025-06-20","current":-0.864859,"twenty":-8.793883,"median":-2.980995,"eighty":-1.008108,"marketCap":125766920},{"date":"2025-06-27","current":-1.031292,"twenty":-8.738225,"median":-2.966787,"eighty":-0.98785,"marketCap":149969489},{"date":"2025-07-03","current":-0.835139,"twenty":-8.660987,"median":-2.95542,"eighty":-0.975365,"marketCap":121445033},{"date":"2025-07-11","current":-1.061012,"twenty":-8.20664,"median":-2.912794,"eighty":-0.974824,"marketCap":154291376},{"date":"2025-07-18","current":-1.209614,"twenty":-8.200961,"median":-2.836066,"eighty":-0.975365,"marketCap":175900813},{"date":"2025-07-25","current":-1.260138,"twenty":-8.178243,"median":-2.779231,"eighty":-0.975365,"marketCap":183248021},{"date":"2025-08-01","current":-1.061012,"twenty":-7.803407,"median":-2.688295,"eighty":-0.975365,"marketCap":154291376},{"date":"2025-08-08","current":-0.98374,"twenty":-7.78069,"median":-2.625776,"eighty":-0.98374,"marketCap":143054469},{"date":"2025-08-15","current":-0.964666,"twenty":-7.68982,"median":-2.585992,"eighty":-0.974824,"marketCap":153089661},{"date":"2025-08-22","current":-0.975567,"twenty":-7.678462,"median":-2.530603,"eighty":-0.962936,"marketCap":154819487},{"date":"2025-08-29","current":-1.008267,"twenty":-7.570554,"median":-2.118493,"eighty":-0.964666,"marketCap":160008967},{"date":"2025-09-05","current":-0.989192,"twenty":-7.52512,"median":-1.993646,"eighty":-0.964666,"marketCap":156981771},{"date":"2025-09-12","current":-1.130894,"twenty":-7.468327,"median":-1.952681,"eighty":-0.972792,"marketCap":179469518},{"date":"2025-09-19","current":-1.365248,"twenty":-7.429707,"median":-1.872701,"eighty":-0.975257,"marketCap":216660791},{"date":"2025-09-26","current":-1.730404,"twenty":-7.422892,"median":-1.802474,"eighty":-0.975365,"marketCap":274609985},{"date":"2025-10-03","current":-1.656828,"twenty":-7.377457,"median":-1.775165,"eighty":-0.975365,"marketCap":262933655},{"date":"2025-10-10","current":-1.923883,"twenty":-7.30249,"median":-1.765048,"eighty":-0.975527,"marketCap":305314409},{"date":"2025-10-17","current":-1.910257,"twenty":-7.150283,"median":-1.79077,"eighty":-0.977747,"marketCap":303152125},{"date":"2025-10-24","current":-1.74403,"twenty":-7.070773,"median":-1.806706,"eighty":-0.98265,"marketCap":276772268},{"date":"2025-10-31","current":-1.839406,"twenty":-7.009436,"median":-1.817606,"eighty":-0.98374,"marketCap":291908252},{"date":"2025-11-07","current":-1.932058,"twenty":-6.429007,"median":-1.834596,"eighty":-0.986404,"marketCap":306611779},{"date":"2025-11-14","current":-1.76583,"twenty":-6.028046,"median":-1.829785,"eighty":-0.98707,"marketCap":280231922},{"date":"2025-11-21","current":-2.023973,"twenty":-5.954216,"median":-1.856881,"eighty":-0.988768,"marketCap":325843504},{"date":"2025-11-28","current":-2.086542,"twenty":-5.791787,"median":-1.873766,"eighty":-0.989487,"marketCap":335916623},{"date":"2025-12-05","current":-2.132789,"twenty":-5.650939,"median":-1.874832,"eighty":-0.990456,"marketCap":343361972},{"date":"2025-12-12","current":-2.27425,"twenty":-5.604368,"median":-1.895008,"eighty":-0.995653,"marketCap":366135981},{"date":"2025-12-19","current":-1.904276,"twenty":-5.571428,"median":-1.899357,"eighty":-1.000453,"marketCap":306573190},{"date":"2025-12-26","current":-2.445634,"twenty":-5.541896,"median":-1.907532,"eighty":-1.00316,"marketCap":393727568},{"date":"2026-01-02","current":-3.335677,"twenty":-5.503276,"median":-1.923883,"eighty":-1.005937,"marketCap":537017328},{"date":"2026-01-09","current":-2.998561,"twenty":-5.448754,"median":-1.93164,"eighty":-1.007666,"marketCap":482744300},{"date":"2026-01-16","current":-3.094373,"twenty":-5.404456,"median":-1.947802,"eighty":-1.008709,"marketCap":498169266},{"date":"2026-01-23","current":-3.729571,"twenty":-5.372651,"median":-1.953858,"eighty":-1.010478,"marketCap":600431076},{"date":"2026-01-30","current":-2.913395,"twenty":-5.344255,"median":-1.965361,"eighty":-1.010992,"marketCap":469033219},{"date":"2026-02-06","current":-2.579827,"twenty":-5.065967,"median":-1.978384,"eighty":-1.01346,"marketCap":415331486},{"date":"2026-02-13","current":-2.611764,"twenty":-5.054609,"median":-2.003915,"eighty":-1.013717,"marketCap":420473142},{"date":"2026-02-20","current":-2.87436,"twenty":-4.986457,"median":-2.025703,"eighty":-1.014247,"marketCap":462748974},{"date":"2026-02-27","current":-2.881457,"twenty":-4.928528,"median":-2.043785,"eighty":-1.01438,"marketCap":463891564},{"date":"2026-03-06","current":-2.977269,"twenty":-4.827435,"median":-2.086542,"eighty":-1.020777,"marketCap":479316530},{"date":"2026-03-13","current":-3.112116,"twenty":-4.780255,"median":-2.118493,"eighty":-1.024754,"marketCap":501025741},{"date":"2026-03-20","current":-3.030498,"twenty":-4.769593,"median":-2.129165,"eighty":-1.025937,"marketCap":487885955},{"date":"2026-03-27","current":-3.012142,"twenty":-4.692966,"median":-2.151832,"eighty":-1.027873,"marketCap":484930840},{"date":"2026-04-02","current":-3.286851,"twenty":-4.628408,"median":-2.225282,"eighty":-1.029368,"marketCap":530192007},{"date":"2026-04-10","current":-3.590425,"twenty":-4.584311,"median":-2.250455,"eighty":-1.030802,"marketCap":579160710},{"date":"2026-04-17","current":-3.571686,"twenty":-4.573206,"median":-2.388506,"eighty":-1.03519,"marketCap":576137951},{"date":"2026-04-24","current":-3.358479,"twenty":-4.567056,"median":-2.487395,"eighty":-1.037789,"marketCap":541746122},{"date":"2026-05-01","current":-3.302191,"twenty":-4.561844,"median":-2.543569,"eighty":-1.038061,"marketCap":532666578},{"date":"2026-05-08","current":-3.489816,"twenty":-4.559102,"median":-2.569768,"eighty":-1.044783,"marketCap":562931724},{"date":"2026-05-15","current":-4.15662,"twenty":-4.534296,"median":-2.581654,"eighty":-1.052413,"marketCap":650095346},{"date":"2026-05-22","current":-3.444499,"twenty":-4.49595,"median":-2.613087,"eighty":-1.058444,"marketCap":538719607},{"date":"2026-05-29","current":-3.347743,"twenty":-4.480996,"median":-2.625776,"eighty":-1.061012,"marketCap":523587034},{"date":"2026-06-05","current":-3.076828,"twenty":-4.471909,"median":-2.688295,"eighty":-1.061714,"marketCap":481215829},{"date":"2026-06-12","current":-3.045866,"twenty":-4.449191,"median":-2.698705,"eighty":-1.063858,"marketCap":476373405},{"date":"2026-06-18","current":-3.11166,"twenty":-4.431665,"median":-2.713919,"eighty":-1.066038,"marketCap":486663555},{"date":"2026-06-26","current":-3.187473,"twenty":-4.412024,"median":-2.725319,"eighty":-1.06856,"marketCap":498520738},{"date":"2026-07-02","current":-3.280765,"twenty":-4.395806,"median":-2.779231,"eighty":-1.069929,"marketCap":513111589},{"date":"2026-07-10","current":-3.813306,"twenty":-4.390126,"median":-2.789213,"eighty":-1.073668,"marketCap":596401029},{"date":"2026-07-17","current":-2.892048,"twenty":-4.36173,"median":-2.806937,"eighty":-1.084606,"marketCap":452316377},{"date":"2026-07-24","current":-2.833741,"twenty":-4.344692,"median":-2.815944,"eighty":-1.092409,"marketCap":443197095},{"date":"2026-07-31","current":-2.911484,"twenty":-4.315412,"median":-2.817583,"eighty":-1.094857,"marketCap":455356137},{"date":"2026-08-07","current":-3.01255,"twenty":-4.26922,"median":-2.824699,"eighty":-1.099263,"marketCap":471162893},{"date":"2026-08-14","current":-3.273726,"twenty":-4.239266,"median":-2.836847,"eighty":-1.106454,"marketCap":499695027},{"date":"2026-08-21","current":-3.293984,"twenty":-4.227182,"median":-2.842423,"eighty":-1.108015,"marketCap":502787199},{"date":"2026-08-28","current":-3.500618,"twenty":-4.222326,"median":-2.869037,"eighty":-1.115418,"marketCap":534327356},{"date":"2026-09-04","current":-3.383121,"twenty":-4.213489,"median":-2.87436,"eighty":-1.117439,"marketCap":516392757},{"date":"2026-09-11","current":-2.977956,"twenty":-4.201242,"median":-2.881457,"eighty":-1.123506,"marketCap":454549313},{"date":"2026-09-18","current":-2.852356,"twenty":-4.185897,"median":-2.878979,"eighty":-1.129545,"marketCap":435377845},{"date":"2026-09-25","current":-2.832097,"twenty":-4.18008,"median":-2.881457,"eighty":-1.131212,"marketCap":432285673},{"date":"2026-10-02","current":-2.64167,"twenty":-4.175257,"median":-2.87436,"eighty":-1.131424,"marketCap":403219254},{"date":"2026-10-09","current":-2.503914,"twenty":-4.171853,"median":-2.867263,"eighty":-1.133757,"marketCap":382192483},{"date":"2026-10-12","current":-2.588999,"twenty":-4.171771,"median":-2.865887,"eighty":-1.134535,"marketCap":395179607}],"updateTime":1791940387089},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KYTX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672761735","title":"健康快讯：研究显示，阑尾切除与结直肠癌风险降低有关","url":"https://stock-news.laohu8.com/highlight/detail?id=2672761735","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672761735?lang=zh_cn&edition=fundamental","pubTime":"2026-10-02 03:30","pubTimestamp":1790883049,"startTime":"0","endTime":"0","summary":"健康快讯：研究显示，阑尾切除与结直肠癌风险降低有关《Health Rounds》荣获2026年出版商通讯奖“最佳科学通讯”奖，每周二和周四发布。切除发炎的阑尾可能降低结直肠癌风险一项针对超过30,000例病例的分析显示，接受阑尾炎手术的患者，其患结直肠癌的风险显著低于仅接受抗生素治疗的患者。在控制了个体风险因素后，阑尾切除术与后续结直肠癌诊断的相对风险降低58%相关。所有受试者均患有糖尿病或肥胖症，或两者兼有。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nL4T45N1HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669678594","title":"Kyverna股价上涨，因细胞疗法在罕见神经疾病中显现持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2669678594","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669678594?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 19:22","pubTimestamp":1790248938,"startTime":"0","endTime":"0","summary":"BUZZ-Kyverna股价上涨，因细胞疗法在罕见神经疾病中显现持久疗效9月24日-** 生物技术公司Kyverna Therapeutics（KYTX.O）的股价在盘前交易中上涨6.1%，至7.50美元** 该公司表示，其实验性细胞疗法miv-cel在治疗僵人综合征（一种会导致严重肌肉僵硬和痉挛的罕见疾病）方面，效果可持续一年** 95% 实现显著活动能力改善的患者在一年后仍维持该疗效；92% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4T45G0WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198928762","title":"Kyverna Therapeutics公布Miv-Cel治疗僵人综合征与全身性重症肌无力一年期积极数据：持久临床缓解与良好安全性获验证","url":"https://stock-news.laohu8.com/highlight/detail?id=1198928762","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198928762?lang=zh_cn&edition=fundamental","pubTime":"2026-09-24 18:04","pubTimestamp":1790244272,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公布Miv-Cel治疗僵人综合征与全身性重症肌无力一年期积极数据：持久临床缓解与良好安全性获验证","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110937187","title":"Kyverna Therapeutics 与 Elevatebio 达成 Miv-Cel 商业生产与供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1110937187","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110937187?lang=zh_cn&edition=fundamental","pubTime":"2026-07-27 20:02","pubTimestamp":1785153775,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics 与 Elevatebio 正式签署了一项针对 Miv-Cel 的商业化生产及供应协议。这一合作标志着双方在细胞治疗领域的战略布局迈出了关键一步，旨在确保 Miv-Cel 能够顺利进入规模化生产阶段，并满足未来市场的潜在需求。通过整合 Elevatebio 的制造专长与 Kyverna 的研发能力，该协议有望加速这一创新疗法的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653759874","title":"生物技术专家希望美国食品药品监督管理局（FDA）的药物评审基于科学，而非政治","url":"https://stock-news.laohu8.com/highlight/detail?id=2653759874","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653759874?lang=zh_cn&edition=fundamental","pubTime":"2026-07-22 18:01","pubTimestamp":1784714498,"startTime":"0","endTime":"0","summary":"生物技术专家希望美国食品药品监督管理局的药物评审基于科学，而非政治生物技术投资者希望监管具有可预测性马斯克的DOGE导致FDA裁减了3,000多个职位FDA现获准招聘2,200名员工特朗普政府正在考虑三位FDA局长候选人Deena Beasley路透7月22日-生物技术专家和行业高管认为，去年曾遭受裁员冲击的美国食品药品监督管理局计划招聘数千名员工并更新临床试验标准，这一举措令人鼓舞，但他们希望获得保证，确保政治因素不会干预该机构的药物审查流程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL4T43O0TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","LGHT","KYTX","BK4585","BK4139","MRNX","BK4548","BK4505","IDNA","MRNA","BK4501","WDNA","BK4533","MRNY","GNOM","NKTX","BK4551","BK4534","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650634136","title":"纳斯达克生物科技指数一度跌超3%，成分股Kyverna Therapeutics目前跌12.45%，Prime Medi","url":"https://stock-news.laohu8.com/highlight/detail?id=2650634136","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650634136?lang=zh_cn&edition=fundamental","pubTime":"2026-07-10 22:49","pubTimestamp":1783694978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","SIGA","NBI","MESO","BK4583","BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131729514","title":"Kyverna Therapeutics任命Ritesh Srivastava为首席法律与合规官，强化领导团队以支持商业化阶段转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1131729514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131729514?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 20:01","pubTimestamp":1782129684,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics已正式任命Ritesh Srivastava担任公司首席法律与合规官。这一关键人事任命旨在显著增强公司的领导层实力，为其向商业化阶段的战略转型提供坚实支撑。Srivastava先生将负责领导公司的整体法律事务、合规体系构建以及企业治理工作，其丰富的专业经验预计将为Kyverna Therapeutics下一阶段的发展带来重要助力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641220164","title":"《健康巡诊》：CAR-T疗法为移植选择有限的肾病患者带来希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2641220164","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641220164?lang=zh_cn&edition=fundamental","pubTime":"2026-06-05 03:54","pubTimestamp":1780602855,"startTime":"0","endTime":"0","summary":"CAR-T细胞疗法为配型困难的患者开启肾移植新希望研究人员发现，最初用于治疗血液癌症的CAR-T细胞疗法，也能让通常不符合移植条件的患者获得肾脏移植机会，这对于治疗选择有限的患者而言，可能是一个重大突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nL4S42C1OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641164227","title":"《健康巡诊》：CAR-T疗法为移植选择有限的肾病患者带来希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2641164227","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641164227?lang=zh_cn&edition=fundamental","pubTime":"2026-06-05 03:54","pubTimestamp":1780602855,"startTime":"0","endTime":"0","summary":"CAR-T细胞疗法为配型困难的患者开启肾移植新希望研究人员发现，最初用于治疗血液癌症的CAR-T细胞疗法，也能让通常不符合移植条件的患者获得肾脏移植机会，这对于治疗选择有限的患者而言，可能是一个重大突破。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nL4T42C1OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198073291","title":"Kyverna Therapeutics在欧洲风湿病学年会上公布Miv-Cel最新数据，显示其对ACPA阳性、难治性类风湿关节炎疾病活动度有显著降低作用","url":"https://stock-news.laohu8.com/highlight/detail?id=1198073291","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198073291?lang=zh_cn&edition=fundamental","pubTime":"2026-06-03 20:01","pubTimestamp":1780488084,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics在欧洲风湿病学大会上公布了其CAR-T细胞疗法候选药物miv-cel的更新数据。数据显示，在接受治疗的抗瓜氨酸蛋白抗体阳性、且对现有疗法反应不佳的难治性类风湿关节炎患者中，该疗法能显著降低疾病活动度。此次公布的数据进一步证实了miv-cel在这一患者群体中的潜力。Kyverna Therapeutics专注于开发用于自身免疫性疾病的工程化T细胞疗法。公司表示，这些积极数据支持了miv-cel的持续临床开发计划，旨在解决严重自身免疫性疾病领域未被满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160299832","title":"Kyverna Therapeutics任命神经学与罕见疾病领域资深商业领袖Nadia Dac为首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1160299832","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160299832?lang=zh_cn&edition=fundamental","pubTime":"2026-05-04 20:02","pubTimestamp":1777896146,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics宣布任命纳迪亚·达克（Nadia Dac）担任首席商务官一职。达克女士在神经学及罕见疾病领域拥有深厚的商业化领导经验，将为公司战略发展注入关键动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162434050","title":"Kyverna Therapeutics股价大涨7.3% 罕见肌肉疾病细胞疗法中期数据表现强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=1162434050","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162434050?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 21:33","pubTimestamp":1776864795,"startTime":"0","endTime":"0","summary":"Kyverna Therapeutics公司股价今日显著上扬，涨幅达7.3%。这一积极市场反应源于该公司针对罕见肌肉疾病的细胞疗法在中期临床试验中取得了令人鼓舞的成果。\n试验数据显示，该疗法在中期阶段展现出强劲的有效性和可控的安全性特征，为后续研发注入了信心。受此利好消息推动，投资者对该公司前景的乐观情绪明显升温，直接反映在股价的强势表现上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043257","title":"BUZZ--美国股票走势-Adobe、GE Vernova、Calix","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043257","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043257?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 19:38","pubTimestamp":1776857889,"startTime":"0","endTime":"0","summary":".N** Intuitive Surgical Inc ISRG.O:BUZZ - 因第一季度盈利超出预期而上涨。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4S41517R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSH","STX","DJTU","SGXZ99366536.SGD","NEMG","GEVG","ADBE","LU0354030438.USD","AMRX","BOEU","ADBG","GEV","TRUMP.USD.CC","DHR","GEVX","LU0889566641.SGD","TEL","BK4210","BOED","BOEG","HL","IE0004445239.USD","BA","LU1923622614.USD","LU1951198990.SGD","DJT","LU0266512473.USD","LU2023250504.SGD","NEM","CALX","HLXX","LU0006306889.USD","LU1046421795.USD","NWMX","DGX","LU0320765059.SGD","LU0472753341.HKD","KYTX","AU","LU1548497426.USD","TFX","ISUL","ISRG","LU1061106388.HKD","LU1280957306.USD","LU2360107325.USD","TH","LU0238689110.USD","CDE","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629017577","title":"BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2629017577","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629017577?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 18:33","pubTimestamp":1776854031,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4T4150ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115847455","title":"Kyverna Therapeutics股价盘前飙升21% 中期试验显示其疗法改善僵人综合征患者活动能力","url":"https://stock-news.laohu8.com/highlight/detail?id=1115847455","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115847455?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 18:20","pubTimestamp":1776853224,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics的股价在盘前交易中大幅上涨21%，此前该公司宣布其针对僵人综合征的疗法在中期临床试验中显示出能够显著改善患者的行动能力。\n这一积极数据提振了投资者信心，推动该公司股价在开盘前出现强劲走势。僵人综合征是一种罕见的神经系统疾病，会导致患者肌肉僵硬和痉挛，严重影响日常活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113314168","title":"Kyverna Therapeutics公布KYSA-8试验主要分析结果：Miv-Cel治疗SPS取得积极成效","url":"https://stock-news.laohu8.com/highlight/detail?id=1113314168","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113314168?lang=zh_cn&edition=fundamental","pubTime":"2026-04-22 06:52","pubTimestamp":1776811935,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics Inc (KYTX) 近日宣布，其针对僵人综合征（SPS）的嵌合抗原受体T细胞疗法Miv-Cel（KYV-101），在名为KYSA-8的临床试验中完成了主要分析。结果显示，该试验达到了预设的主要终点，展现出显著的治疗潜力。\n此次公布的数据进一步验证了Miv-Cel在改善SPS患者临床症状方面的积极效果。公司表示，详细结果将在未来的医学会议上公布，并计划与监管机构讨论后续开发策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148269805","title":"Kyverna Therapeutics公布Miv-Cel治疗全身型重症肌无力二期长期积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1148269805","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148269805?lang=zh_cn&edition=fundamental","pubTime":"2026-04-20 20:05","pubTimestamp":1776686742,"startTime":"0","endTime":"0","summary":"生物技术公司Kyverna Therapeutics Inc (KYTX) 近日宣布，其针对全身型重症肌无力的候选疗法Miv-Cel在二期临床试验中取得积极长期随访结果。数据显示，该疗法在延长观察期内持续展现出良好的安全性与耐受性特征，同时关键疗效指标维持稳定改善趋势。这一进展为后续关键临床试验的设计与推进提供了重要依据，也增强了业界对该细胞疗法潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187806317","title":"Kyverna Therapeutics：24周时100%患者实现MG-ADL与QMG快速持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1187806317","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187806317?lang=zh_cn&edition=fundamental","pubTime":"2026-04-20 20:03","pubTimestamp":1776686634,"startTime":"0","endTime":"0","summary":"临床数据显示，Kyverna Therapeutics在研疗法取得突破性进展——所有受试患者在24周观察期内均展现出肌无力日常生活活动量表和定量肌力测试评分的快速且持久的改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}